2. Peptides
  3. Peptide and Derivatives
  4. Cell-adhesion Peptides

Cell-adhesion Peptides

Cell-adhesion Peptides (74):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P0023
    Cyclo(-RGDfK) 161552-03-0 ≥98.0%
    Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
    Cyclo(-RGDfK)
  • HY-12290
    Arg-Gly-Asp-Ser 91037-65-9 99.93%
    Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
    Arg-Gly-Asp-Ser
  • HY-P0131A
    Laminin (925-933)(TFA) 2828432-44-4 99.75%
    Laminin (925-933) (TFA) is a peptide derived from residues 925-933 of the Laminin B1 chain that binds to the laminin receptor.
    Laminin (925-933)(TFA)
  • HY-P0122
    iRGD peptide 1392278-76-0 99.57%
    iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
    iRGD peptide
  • HY-P0278
    RGD 99896-85-2 98.37%
    RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
    RGD
  • HY-P1740A
    RGD peptide (GRGDNP) (TFA) 99.94%
    RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation.
    RGD peptide (GRGDNP) (TFA)
  • HY-P0290
    GRGDSP 91037-75-1 99.91%
    GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.
    GRGDSP
  • HY-P1740
    RGD peptide (GRGDNP) 114681-65-1 99.63%
    RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation.
    RGD peptide (GRGDNP)
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) 862772-11-0 99.70%
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors.
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
  • HY-P0278A
    RGD Trifluoroacetate 2378808-45-6 99.75%
    RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins.
    RGD Trifluoroacetate
  • HY-P0023A
    Cyclo(-RGDfK) TFA 500577-51-5 99.82%
    Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
    Cyclo(-RGDfK) TFA
  • HY-P4322
    H-Ile-Lys-Val-Ala-Val-OH 131167-89-0 99.12%
    H-Ile-Lys-Val-Ala-Val-OH is one of the most potent active sites of laminin-1. H-Ile-Lys-Val-Ala-Val-OH promotes cell adhesion, neurite outgrowth, and tumor growth. H-Ile-Lys-Val-Ala-Val-OH stimulates BMMSC population growth and proliferation by activating MAPK/ERK1/2 and PI3K/Akt signalling pathways.
    H-Ile-Lys-Val-Ala-Val-OH
  • HY-P0295
    Gly-Arg-Gly-Asp-Ser 96426-21-0 99.87%
    Gly-Arg-Gly-Asp-Ser is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC50 of ∼5 and ∼6.5 μM
    Gly-Arg-Gly-Asp-Ser
  • HY-P0290A
    GRGDSP TFA ≥98.0%
    GRGDSP (TFA) is an integrin inhibitor.
    GRGDSP TFA
  • HY-P0122B
    iRGD peptide 1 TFA 98.45%
    iRGD peptide 1 TFA is the prototypic tumor-specific tissue-penetrating peptide, which delivers agents deep into extravascular tumor tissue. iRGD peptide 1 TFA has anti-metastatic activity.
    iRGD peptide 1 TFA
  • HY-P1408A
    Obtustatin triacetate 99.66%
    Obtustatin triacetate is a 41-residue non-RGD disintegrin. Obtustatin triacetate can be isolated from the venom of Vipera lebetina obtusa. Obtustatin triacetate is a potent and selective inhibitor of integrin α1β1 adhesion to type IV collagen. Obtustatin triacetate inhibits angiogenesis and may be used in cancer research.
    Obtustatin triacetate
  • HY-P1741
    Fibrinogen-Binding Peptide 137235-80-4 99.83%
    Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin.
    Fibrinogen-Binding Peptide
  • HY-P0031
    Cyclo(RADfK) 756500-23-9 99.46%
    Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.
    Cyclo(RADfK)
  • HY-P2532
    Integrin Binding Peptide 278792-07-7 99.73%
    Integrin Binding Peptide is derived by fibronectin. Integrin Binding Peptide can be used for PEG hydrogel preparation.
    Integrin Binding Peptide
  • HY-P0314A
    Arg-Gly-Asp-Cys TFA 2171504-22-4 99.95%
    Arg-Gly-Asp-Cys TFA is the binding motif of fibronectin to cell adhesion molecules. Arg-Gly-Asp-Cys TFA can inhibit platelet aggregation and fibrinogen binding.
    Arg-Gly-Asp-Cys TFA